Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02336347 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study Comparing AVP-786 With AVP-923
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02336347 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 62 participants.
The verdict
NCT02336347, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
To compare pharmacokinetics (PK) of AVP-786 (deuterated \[d6\] dextromethorphan hydrobromide \[d6-DM\]/quinidine sulfate \[Q\]) to AVP-923 (dextromethorphan hydrobromide \[DM\]/Q) at steady state.
Interventions
- DRUG AVP-923
- DRUG AVP-786
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2014-05-01 |
| Est. Completion | 2015-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02336347
The ClinicalTrials.gov registry entry for NCT02336347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AVP-923 is the first listed.
NCT02336347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02336347 about?
NCT02336347 is a clinical study titled "A Phase 1 Study Comparing AVP-786 With AVP-923". To compare pharmacokinetics (PK) of AVP-786 (deuterated \[d6\] dextromethorphan hydrobromide \[d6-DM\]/quinidine sulfate \[Q\]) to AVP-923 (dextromethorphan hydrobromide \[DM\]/Q) at steady state.
What is the current status of trial NCT02336347?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2014-05-01. Estimated completion is 2015-03-01.
What interventions are being tested in trial NCT02336347?
The interventions under investigation include: AVP-923 (DRUG), AVP-786 (DRUG).
Who is sponsoring clinical trial NCT02336347?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.